Literature DB >> 10394482

Smoking and therapeutic response to clozapine in patients with schizophrenia.

J P McEvoy1, O Freudenreich, W H Wilson.   

Abstract

BACKGROUND: Of patients with schizophrenia, 70 to 80% smoke. Nicotine corrects certain information processing and cognitive psychomotor deficits seen in many patients with schizophrenia. Clozapine, but not conventional antipsychotics, has been shown to correct some of these deficits.
METHODS: We assessed psychopathology and smoking in 70 patients with treatment refractory schizophrenia (55 smokers and 15 nonsmokers) at baseline when they were receiving conventional antipsychotics and again after they were switched to clozapine.
RESULTS: Smokers showed significantly greater therapeutic response to clozapine than nonsmokers. Smokers smoked less when treated with clozapine than when treated with conventional antipsychotics.
CONCLUSIONS: Certain patients with schizophrenia have contributing pathophysiologic mechanisms that respond favorably to either nicotine or clozapine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394482     DOI: 10.1016/s0006-3223(98)00377-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  38 in total

1.  Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.

Authors:  Serge Sevy; Delbert G Robinson; Suzanne Sunday; Barbara Napolitano; Rachel Miller; Joanne McCormack; John Kane
Journal:  Psychiatry Res       Date:  2011-06-01       Impact factor: 3.222

Review 2.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

4.  IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs.

Authors:  Vanessa Cousins; Jed E Rose; Edward D Levin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-06-20       Impact factor: 5.067

Review 5.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

6.  The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets.

Authors:  N Sasaki; M Iwase; Y Uchizono; U Nakamura; H Imoto; S Abe; M Iida
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

Review 7.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

9.  Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Charles Campbell; Sharon L Walsh
Journal:  Exp Clin Psychopharmacol       Date:  2014-01-27       Impact factor: 3.157

Review 10.  [Why do schizophrenic patients smoke?].

Authors:  K Cattapan-Ludewig; S Ludewig; E Jaquenoud Sirot; M Etzensberger; F Hasler
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.